Vibrio Infections 

  • Author: Hoi Ho, MD; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Aug 15, 2011
 

Background

Vibrio infections are largely classified into two distinct groups: Vibrio cholera infections and noncholera Vibrio infections. Historically, the noncholera Vibrio species are classified as halophilic or nonhalophilic, depending on their requirement of sodium chloride for growth.

Because most Vibrio infections are associated with the consumption of contaminated food, these infections are often considered a foodborne disease. The prevalence of noncholera Vibrio infections in the United States appears to have increased in recent years. The combination of increased water temperature and salinity where shellfish are harvested may contribute to increased contamination rates of shellfish. Although many foodborne diseases are not reportable in the United States, the Centers for Disease Control and Prevention (CDC) estimates that approximately 48 million Americans (or roughly 1 in 6) get sick with foodborne diseases annually. Of these, 128,000 are hospitalized and 3000 die.[1]

Since 1988, the CDC has maintained a voluntary surveillance system for culture-confirmed Vibrio infections in the Gulf Coast region (Alabama, Florida, Louisiana, Mississippi, and Texas). In 2007, the surveillance was expanded to national notification of infections caused by any Vibrio species. In 2011, the CDC estimates 45,000 cases (90% confidence interval [CI], 23,000-75,000) of Vibrio parahaemolyticus yearly in the United States, 207 cases (90% CI, 138-287) of Vibrio Vulnificus, and 35,000 cases (90% CI, 22,000-52,000) of Vibrio species; this is an estimate owing to underreporting.[2]

While the estimated incidence of infection with Shiga toxin–producing Escherichia coli O157:H7 (STEC O157) and species of Campylobacter,Cryptosporidium, Listeria,Salmonella, and Yersinia significantly decreased from 1998 to 2010, the incidence of Vibrio infections during this period increased 115% (95% CI, 63%-187%).[3]

Although Vibrio parahaemolyticus is the most common noncholera Vibrio species reported to cause infection, Vibrio vulnificus is associated with up to 94% of noncholera Vibrio infection-related deaths. Because clinical laboratories do not routinely use the selective medium thiosulfate-citrate-bile salts-sucrose (TCBS) for stool culture, many cases of Vibriogastroenteritis are not identified.[4]

A review of Cholera and Other Vibrio Illness Surveillance (COVIS) data from 1997-2006 reported that of 4754 Vibrio species–related illnesses, 1210 (25%) were nonfoodborne Vibrio infections (NFVIs).[5] Of note, the species most frequently isolated in these NFVIs was V vulnificus (35%), followed by Vibrio alginolyticus (29%), and V parahaemolyticus (19%). Not surprisingly, the majority of the reports came from the Gulf Coast region under surveillance (57%), followed by the Atlantic region (24%), the Pacific region (16%), and noncoastal areas (3%). Vibrio was identified in wounds (68%), blood (20%), and “other” (18%).

In the event of a natural disaster, the disturbance to the environment may increase the risk of infectious diseases such as Vibrio infections. During the 2 weeks following Hurricane Katrina in August 2005, the CDC reported 22 new cases of Vibrio infections in Louisiana and Mississippi. V vulnificus accounted for most (82%) of these wound-associated infections.[6] The increased incidence of Vibrio wound infections in the residents of Gulf Coast states was most likely associated with the exposure of skin and soft-tissue injuries to the contaminated floodwaters.[6]

Next

Pathophysiology

The Vibrionaceae family includes the genera Vibrio, Plesiomonas, and Aeromonas. Members of the family Vibrionaceae are natural inhabitants of sea water but can also be found in fresh water. Vibrio species are oxidase-positive, gram-negative bacilli. With the exception of nonhalophilic Vibrio species, such as Vibrio cholerae and Vibrio mimicus, all Vibrio species require saline for growth.

Vibrio species can produce multiple extracellular cytotoxins and enzymes that are associated with extensive tissue damage and that may play a major role in the development of sepsis (see Table 1).

Table 1. Noncholera Vibrio Species and Associated Clinical Presentations (Open Table in a new window)

Infection TypeNoncholera Vibrio SpeciesCytotoxins/Enzymes
GastroenteritisV parahaemolyticus



Non-01 V cholerae



Vibrio fluvialis



V mimicus



Vibrio furnissii



Vibrio hollisae



Vibrio alginolyticus



V vulnificus



Cytotoxin



Hemolysin



Wound infectionV alginolyticus



V vulnificus



Non-01 V cholerae



Vibrio damsela



Vibrio carchariae



V fluvialis



V parahaemolyticus



V mimicus



Protease



Hemolysin



Lipase



DNAase



Cytolysin



SepticemiaV vulnificus



V fluvialis



V damsela



Non-01 V cholerae



Vibrio cincinnatiensis



Proteases



Endotoxic lipopolysaccharide



V vulnificus lives in areas where the temperature exceeds 18°C. In the United States, it is found in the coastal waters of the Gulf of Mexico, New England, and the northern Pacific. Low-to-moderate salinity (15-25 parts per thousand) provides the most favorable growing condition for V vulnificus, and, conversely, high salinity (>25 parts per thousand) adversely affects its survival. Similar to the effect of high salinity, low seawater temperature (< 10°C) significantly inhibits the growth of V vulnificus. V vulnificus is ingested by filter-feeding mollusks such as oysters, mussels, clams, and scallops. During the warmer months, the concentration of bacteria can be as high as 1 X 106 bacteria per gram of oyster.[7]

Several mechanisms contribute to the virulence of V vulnificus. Iron is an important growth factor. However, because free iron is virtually absent in humans, the organism produces siderophores that acquire iron from transferrin or lactoferrin and deliver it to the bacteria. Conversely, the inability to produce siderophores leads to reduction of virulence. Hepcidin, a natural cysteine-rich peptide, has recently been suggested to possess important antibacterial activity. It is possible that inadequate expression of hepcidin in patients with liver disease predisposes them to serious infections, including those caused by Vibrio species.[8, 9]

Clinical conditions associated with increased free iron, such as hemochromatosis or hemolytic anemia, represent a major risk factor for disseminated Vibrio infections. In addition, V vulnificus produces several other virulence factors, including proteases, hemolysins, and cytolysins. One in particular, a thermolysin-like metalloprotease, activates the bradykinin pathway, causing an increase in vascular permeability. This metalloprotease is far more efficient at activating human enzymes than those of other Vibrio species, possibly explaining why V vulnificus causes severe skin damage and necrotizing fasciitis.[10]

A recent study in mice, however, has shown that metalloprotease is not necessarily fundamental for the virulence of V vulnificus. The absence of protease activity resulted in increased cytolysin activity that may have contributed to the enhanced virulence.[11] On animal models, a protease-deficient mutant of V vulnificus was as virulent as the wild-type strain.

The ability of V vulnificus to express a capsular polysaccharide on its cell surface also corresponds to an increased virulence. It allows the bacteria to circumvent the host’s immune system and to cause extensive tissue damage and septicemia. Besides environmental factors such as temperature and aeration, V vulnificus can also alter the amount of capsular polysaccharide displayed on its surface.[12]

Recently, the gene pyrH has been demonstrated as essential for in vivo survival and growth of V vulnificus in infected mice and is likely associated with its virulence. Clinical isolates of V vulnificus, but not environmental isolates , caused extensive damage to macrophages in animal models, possibly explaining the lethal effects of this infection. PyrH plays a significant role in catalyzing the phosphorylation of UMP to UDP, which is subsequently used in the synthesis of pyrimidines. The numerous attempts to uncover the biochemical profile of pyrH may lead to a novel set of antimicrobial agents.[13] In addition, photodynamic therapy (PDT) with toluidine blue in mice has been found to be curative in otherwise-fatal V vulnificus wound infections.[14]

Two major virulence factors in pathogenic V parahaemolyticus strains include a thermostable direct hemolysin (TDH) and a thermostable direct hemolysin-related hemolysin (TRH). TDH induces beta-hemolysis termed the Kanagawa phenomenon on a Wagatsuma blood agar and possesses both enterotoxic and cytotoxic effects, which gives rise to the watery diarrhea associated with V parahaemolyticus infection.[15, 16]

For additional information on cutaneous V vulnificus infections, see the article Vibrio Vulnificus.

Previous
Next

Epidemiology

Frequency

United States

Between 1998 and 2010, the incidence of Vibrio infections increased by more than 115%. The CDC estimates that 80,000 Vibrio infections (200 V vulnificus, 45,000 V parahaemolyticus, and 35,000 Vibrio species.) and approximately 100 deaths related to Vibrio infections may occur annually in the United States.[2] Vibrio infections are acquired through consumption of contaminated raw or undercooked shellfish such as oysters, clams, mussels, or crabs. Exposure of wounds to contaminated seawater, injury caused by contaminated seashells, and shark and alligator bites are potential alternative sources of infection (see Table 2).

V parahaemolyticus is the leading cause of seafood-associated gastroenteritis in the United States. During a large outbreak of gastroenteritis in July 2004 in the Gulf of Alaska, V parahaemolyticus caused illness in almost one third of cruise ship passengers who consumed Vibrio -contaminated oysters. From May to July 2006, health departments of New York City, New York state, Oregon, and Washington state reported a total of 177 cases of V parahaemolyticus gastroenteritis. Of these reported cases, 113 (64%) involved residents of Washington state.[17]

Table 2. Clinical Presentation Rates of Pathogenic Vibrio Infections (Open Table in a new window)

Vibrio SpeciesGastroenteritis



(%)



Wound Infection



(%)



Septicemia



(%)



Miscellaneous



(%)



V parahaemolyticus593452
V vulnificus545437
Non-01 V cholerae67915
V alginolyticus5-1271110-15
V mimicus8533
V fluvialis73106
V damselaRare>95Rare
V furnissii>90RareRare
Vibrio metschnikoviiCommonRareRare
V hollisae8575
V cincinnatiensisRareRareRareMeningitis

International

Noncholera Vibrio infections are commonly reported in areas such as Japan, Taiwan, China, Hong Kong, Korea, Italy, and Israel. The high prevalence of hepatitis B infections in areas such as China and Taiwan may also contribute to the high incidence of severe noncholera Vibrio infections.

Contrary to epidemiologic patterns of Vibrio infections, only sporadic cases were reported among survivors and injured individuals following the tsunami that devastated Thailand, Indonesia, and India in December 2004.

Despite a high annual estimated incidence of V vulnificus septicemia in Japan (425 cases; 95% CI, 238-752), a survey of registered emergency physicians in Japan surprisingly revealed that only 15.7% (95% CI, 11.3-21.0) of responding physicians had a basic knowledge of this frequently fatal infection.[18]

Mortality/Morbidity

According to CDC estimates, foodborne diseases cause approximately 48 million illnesses, 128,000 hospitalizations, and 3000 deaths annually in the United States.[1]

Foodborne noncholera Vibrio infections may occur at rate of 0.2-0.3 case per 100,000 population. In 2011, CDC estimates 45,000 cases of V parahaemolyticus infection annually, resulting in 129 hospitalizations (90% CI, 66-219) and 5 deaths (90% CI, 0-22). Two hundred and seven cases of V vulnificus infection are estimated to occur annually (90% CI, 138-287), resulting in 200 hospitalizations (90% CI, 120-303) and 77 deaths (90% CI, 43-120).[2]

Although Vibrio infections are not as common as Campylobacter, Salmonella, or Listeria infections, more patients with Vibrio infections die because of the high mortality rate (35-50%) associated with V vulnificus septicemia.

Among all foodborne diseases, V vulnificus infection is associated with the highest case fatality rate (39%).

Patients with cirrhosis who consumed raw oysters were 80 times more likely to develop V vulnificus infection and 200 times more likely to die of the infection than those without liver disease who consumed raw oysters.[19]

Regardless of pre-existing conditions, the mortality risk increases in patients with V vulnificus infection who are hospitalized more than two days after symptoms develop (OR, 2.9; 95% CI, 1.8-4.8).[20]

A delay in performing the first fasciotomy (>24 h) after development of clinical symptoms in patients with V vulnificus necrotizing fasciitis was associated with 5-fold increase in the mortality risk.

Race

Vibrio infections have no racial predilection. Because Vibrio species are natural inhabitants of sea water, Vibrio infections are more commonly reported in states or countries bordered by large bodies of sea water. Persons with underlying medical conditions, such as alcoholism, cirrhosis, or malignancy, and recipients of organ transplants are at increased risk of Vibrio infections and serious complications. Patients with end-stage renal failure who are on continuous ambulatory peritoneal dialysis (CAPD) may develop peritonitis after eating or handling raw sea fish.

Sex

Vibrio infections can occur in all persons, regardless of sex. V vulnificus infections were reported in women who engaged in sexual intercourse in brackish water of the Gulf of Mexico. In general, V vulnificus infections are more common in males (82%), according to most reports.

Age

Persons of any age who consume or are exposed to Vibrio- contaminated food or water are at risk of developing Vibrio infection, especially if they have underlying medical conditions such as advanced liver disease.

Most patients with Vibrio wound infections and septicemia are aged 50-60 years.

Previous
 
 
Contributor Information and Disclosures
Author

Hoi Ho, MD  Associate Dean for Faculty Affairs and Development, Professor, Department of Internal Medicine, Director, Center for Advanced Teaching and Assessment in Clinical Simulation (ATACS), Paul L Foster School of Medicine, Texas Tech University Health Sciences Center; Consulting Physician, University Medical Center

Hoi Ho, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American College of Forensic Examiners, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Coauthor(s)

Ogechika Karl Alozie, MBBS, MPH, AAHIVS  Assistant Professor of Infectious Diseases, Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L Foster School Of Medicine

Ogechika Karl Alozie, MBBS, MPH, AAHIVS is a member of the following medical societies: American Academy of HIV Medicine

Disclosure: Nothing to disclose.

Sun-Yu Tran  Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine

Sun-Yu Tran is a member of the following medical societies: American College of Physicians and Texas Medical Association

Disclosure: Nothing to disclose.

Tony Tran Ho, MS  Texas Tech University School of Medicine

Tony Tran Ho, MS is a member of the following medical societies: American Medical Association and Texas Medical Association

Disclosure: Nothing to disclose.

Thong Huy Do, MD  Staff Physician, Department of Internal Medicine, Thomason Hospital, Texas Tech University

Thong Huy Do, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary D Nettleman, MD, MS, MACP  Professor and Chair, Department of Medicine, Michigan State University College of Human Medicine

Mary D Nettleman, MD, MS, MACP is a member of the following medical societies: American College of Physicians, Association of Professors of Medicine, Central Society for Clinical Research, Infectious Diseases Society of America, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Richard B Brown, MD, FACP  Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine

Richard B Brown, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Eleftherios Mylonakis, MD  Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital

Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous coauthor Wei-L Wu, MS, to the development and writing of this article.

References
  1. 2011 Estimates of foodborne illness in the united states. Available at http://www.cdc.gov/foodborneburden.

  2. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States--major pathogens. Emerg Infect Dis. Jan 2011;17(1):7-15. [Medline].

  3. 3. Vital Signs: Incidence and Trends of Infection with Pathogens Transmitted Commonly Through Food --- Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 1996—2010. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6022a5.htm?s_cid=mm6022a5_w.

  4. Marano NN, Daniels NA, Easton AN, McShan A, Ray B, Wells JG. A survey of stool culturing practices for vibrio species at clinical laboratories in Gulf Coast states. J Clin Microbiol. Jun 2000;38(6):2267-70. [Medline].

  5. Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis. Apr 1 2008;46(7):970-6. [Medline].

  6. Centers for Disease Control and Prevention (CDC). Vibrio illnesses after Hurricane Katrina--multiple states, August-September 2005. MMWR Morb Mortal Wkly Rep. Sep 23 2005;54(37):928-31. [Medline].

  7. Shapiro RL, Altekruse S, Hutwagner L. The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group. J Infect Dis. Sep 1998;178(3):752-9. [Medline].

  8. Brennt CE, Wright AC, Dutta SK. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis. Nov 1991;164(5):1030-2. [Medline].

  9. Hor LI, Chang TT, Wang ST. Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infect Dis. Jan 1999;179(1):275-8. [Medline].

  10. Miyoshi S, Nakazawa H, Kawata K, Tomochika K, Tobe K, Shinoda S. Characterization of the hemorrhagic reaction caused by Vibrio vulnificus metalloprotease, a member of the thermolysin family. Infect Immun. Oct 1998;66(10):4851-5. [Medline].

  11. Shao CP, Hor LI. Metalloprotease is not essential for Vibrio vulnificus virulence in mice. Infect Immun. Jun 2000;68(6):3569-73. [Medline].

  12. Hilton T, Rosche T, Froelich B, Smith B, Oliver J. Capsular polysaccharide phase variation in Vibrio vulnificus. Appl Environ Microbiol. Nov 2006;72(11):6986-93. [Medline].

  13. Lee SE, Kim SY, Kim CM, Kim MK, Kim YR, Jeong K. The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor. Infect Immun. Jun 2007;75(6):2795-801. [Medline].

  14. Wong TW, Wang YY, Sheu HM, Chuang YC. Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus. Antimicrob Agents Chemother. Mar 2005;49(3):895-902. [Medline].

  15. Shirai H, Ito H, Hirayama T, Nakamoto Y, Nakabayashi N, Kumagai K. Molecular epidemiologic evidence for association of thermostable direct hemolysin (TDH) and TDH-related hemolysin of Vibrio parahaemolyticus with gastroenteritis. Infect Immun. Nov 1990;58(11):3568-73. [Medline].

  16. Nishibuchi M, Fasano A, Russell RG, Kaper JB. Enterotoxigenicity of Vibrio parahaemolyticus with and without genes encoding thermostable direct hemolysin. Infect Immun. Sep 1992;60(9):3539-45. [Medline].

  17. Vibrio parahaemolyticus infections associated with consumption of raw shellfish--three states, 2006. MMWR Morb Mortal Wkly Rep. Aug 11 2006;55(31):854-6. [Medline].

  18. Osaka K, Komatsuzaki M, Takahashi H, Sakano S, Okabe N. Vibrio vulnificus septicaemia in Japan: an estimated number of infections and physicians' knowledge of the syndrome. Epidemiol Infect. Oct 2004;132(5):993-6. [Medline].

  19. Haq SM, Dayal HH. Chronic liver disease and consumption of raw oysters: a potentially lethal combination--a review of Vibrio vulnificus septicemia. Am J Gastroenterol. May 2005;100(5):1195-9. [Medline].

  20. Liu JW, Lee IK, Tang HJ, Ko WC, Lee HC, Liu YC. Prognostic Factors and Antibiotics in Vibrio vulnificus Septicemia. Arch Intern Med. Oct 23 2006;166(19):2117-23. [Medline].

  21. Dadisman TA Jr, Nelson R, Molenda JR. Vibrio parahaemolyticus gastroenteritis in Maryland. I. Clinical and epidemiologic aspects. Am J Epidemiol. Dec 1972;96(6):414-26. [Medline].

  22. Howard RJ, Lieb S. Soft-tissue infections caused by halophilic marine vibrios. Arch Surg. Feb 1988;123(2):245-9. [Medline].

  23. Klontz KC, Lieb S, Schreiber M. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med. Aug 15 1988;109(4):318-23. [Medline].

  24. Chuang YC, Ko WC, Wang ST, Liu JW, Kuo CF, Wu JJ. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother. Jun 1998;42(6):1319-22. [Medline].

  25. Anand RG, Lopez FA, deBoisblanc B. Vibrio vulnificus sepsis successfully treated with antibiotics, surgical debridement, and recombinant human activated protein C. J La State Med Soc. May-Jun 2004;156(3):130-3; quiz 133. [Medline].

  26. Mouzin E, Mascola L, Tormey MP. Prevention of Vibrio vulnificus infections. Assessment of regulatory educational strategies. JAMA. Aug 20 1997;278(7):576-8. [Medline].

  27. Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--selected sites, United States, 2003. MMWR Morb Mortal Wkly Rep. Apr 30 2004;53(16):338-43. [Medline].

  28. Hiransuthikul N, Tantisiriwat W, Lertutsahakul K, Vibhagool A, Boonma P. Skin and soft-tissue infections among tsunami survivors in southern Thailand. Clin Infect Dis. Nov 15 2005;41(10):e93-6. [Medline].

  29. Hlady WG, Klontz KC. The epidemiology of Vibrio infections in Florida, 1981-1993. J Infect Dis. May 1996;173(5):1176-83. [Medline].

  30. Hollis DG, Weaver RE, Baker CN. Halophilic Vibrio species isolated from blood cultures. J Clin Microbiol. Apr 1976;3(4):425-31. [Medline].

  31. Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired in the United States--unspecified agents. Emerg Infect Dis. Jan 2011;17(1):16-22. [Medline].

  32. Summary of Notifiable Diseases in United States, 2009. Available at http://www.cdc.gov/mmwr/pdf/wk/mm5853.pdf.

Previous
Next
 
Vibrio infections. Early bullous lesions appear over the dorsum of the foot of a patient with cirrhosis.
Vibrio infections. In a patient with cirrhosis, skin lesion rapidly becomes necrotic.
Vibrio infections. Bullous lesions in a patient with cirrhosis continue to progress, and the patient rapidly develops hypotension and shock despite aggressive medical therapy.
Table 1. Noncholera Vibrio Species and Associated Clinical Presentations
Infection TypeNoncholera Vibrio SpeciesCytotoxins/Enzymes
GastroenteritisV parahaemolyticus



Non-01 V cholerae



Vibrio fluvialis



V mimicus



Vibrio furnissii



Vibrio hollisae



Vibrio alginolyticus



V vulnificus



Cytotoxin



Hemolysin



Wound infectionV alginolyticus



V vulnificus



Non-01 V cholerae



Vibrio damsela



Vibrio carchariae



V fluvialis



V parahaemolyticus



V mimicus



Protease



Hemolysin



Lipase



DNAase



Cytolysin



SepticemiaV vulnificus



V fluvialis



V damsela



Non-01 V cholerae



Vibrio cincinnatiensis



Proteases



Endotoxic lipopolysaccharide



Table 2. Clinical Presentation Rates of Pathogenic Vibrio Infections
Vibrio SpeciesGastroenteritis



(%)



Wound Infection



(%)



Septicemia



(%)



Miscellaneous



(%)



V parahaemolyticus593452
V vulnificus545437
Non-01 V cholerae67915
V alginolyticus5-1271110-15
V mimicus8533
V fluvialis73106
V damselaRare>95Rare
V furnissii>90RareRare
Vibrio metschnikoviiCommonRareRare
V hollisae8575
V cincinnatiensisRareRareRareMeningitis
Table 3. Clinical Signs and Symptoms of Vibrio Infections
Clinical PresentationSymptoms (Frequency)
GastroenteritisDiarrhea (100%)



Abdominal cramps (89%)



Nausea (76%)



Vomiting (55%)



Fever (47%)



Bloody stools (29%)



Headache (24%)



Myalgia (24%)



Wound infectionSwelling (100%)



Pain (100%)



Erythema (100%)



Bullae (30-50%)



Necrosis (30-50%)



Gangrene (< 10%)



SepticemiaFever (>90%)



Hypothermia (< 10%)



Hypotension (100%)



Tachycardia (80-90%)



Shock (50-70%)



Bullae (80-100%)



Acute respiratory distress syndrome (< 5%)



Multiple organ dysfunction (30-50%)



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.